What's new in the 2016 WHO lymphoma classification?
EHA Learning Center, Steven Swerdlow, 184435
Molecular Biology Of Waldenström's Disease
EHA Learning Center, Steven Treon, 184438
Clinical Heterogeneity Of Ambiguous Lineage Leukemias: Search For Optimal Treatment Strategy
EHA Learning Center, O. Hrusak, 184441
From Genetics To Epigenetics In Chronic Myelomonocytic Leukemia
EHA Learning Center, Eric Solary, 184444
Genetic Studies Of Human Erythropoiesis
EHA Learning Center, Vijay Sankaran, 184447
Molecular pathogenesis of Richter syndrome
EHA Learning Center, Gianluca Gaidano, 192912
José Carreras Lecture: AML: The Evil side of gene regulation
EHA Learning Center, Ruud Delwel, 184433
Introduction José Carreras Award & Lecture
EHA Learning Center, Shai Izraeli, 184432
Presentation EHA - José Carreras young investigator award & EHA research grants
EHA Learning Center, Martina Muckenthaler, 184431
Opening address
EHA Learning Center, Tony Green, 184430
PATIENTS WITH LIGHT CHAIN AMYLOIDOSIS TREATED WITH NEOD001 ACHIEVE RAPID ORGAN RESPONSES THAT ARE INDEPENDENT OF PREVIOUS PLASMA CELL-DIRECTED THERAPIES
EHA Learning Center, Morie Gertz, 181391
TP53 MUTATIONS, BUT NOT DELETION OF TP53 AND CDKN2A, HAVE INDEPENDENT PROGNOSTIC VALUE IN MANTLE CELL LYMPHOMA TREATED BY THE NORDIC (MCL2 AND MCL3) REGIMEN
EHA Learning Center, Christian Winther Eskelund, 181396
DEFINITION OF PARTIAL RESPONSE IN YOUNGER AML PATIENTS AFTER FIRST INDUCTION COURSE MAY BE EXTENDED BY INCLUSION OF IMMUNOPHENOTYPIC DETECTION OF MEASURABLE RESIDUAL DISEASE IN CR
EHA Learning Center, Sylvia Freeman, 181401
THERAPEUTIC DISRUPTION OF THE BAFF- B-CELL RECEPTOR (BCR) CROSS-TALK IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS
EHA Learning Center, Alexey Danilov, 181405
TRANSCRIPTOME SEQUENCING REVEALS DISTINCT SUBTYPES OF MYELODYSPLASIA WITH PROGNOSTIC SIGNIFICANCE
EHA Learning Center, Seishi Ogawa, 181410
DELETION OF THE F-BOX PROTEIN NIPA (NUCLEAR INTERACTION PARTNER OF ALK) IMPAIRS NPM-ALK DRIVEN TRANSFORMATION
EHA Learning Center, Lena Johanna Lippert, 181414
CD34+ AND HUMAN INDUCED PLURIPOTENT STEM CELL (IPSC) DIFFERENTIATION TO TRANSFUSION READY RED BLOOD CELLS
EHA Learning Center, Marie-Jose Claessen, 181419
METABOLIC ADAPTATIONS TO TARGETED THERAPY IN FLT3 MUTATED ACUTE MYELOID LEUKAEMIA (AML)
EHA Learning Center, Paolo Gallipoli, 181423
A NOVEL MODEL OF HUMAN LYMPHO-MYELOID PROGENITOR HIERARCHY BASED ON SINGLE CELL FUNCTIONAL AND TRANSCRIPTIONAL ANALYSIS
EHA Learning Center, Dimitrios Karamitros, 181427
TARGETING FLT3 WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS CONFERS POTENT REACTIVITY AGAINST ACUTE MYELOID LEUKEMIA (AML)
EHA Learning Center, HARDIKKUMAR JETANI, 181432
PHASE I, OPEN-LABEL TRIAL OF ANTI-BCMA CHIMERIC ANTIGEN RECEPTOR T CELLS IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Wanggang Zhang, 181390
ANALYSIS AND CHARACTERIZATION OF HEMATOLOGIC CANCERS USING A COMPREHENSIVE NGS PANEL COMPRISED OF DNA AND RNA BAITS TARGETING 704 GENES
EHA Learning Center, Timothy Stenzel, 181395
LEUKEMIC STEM CELL FREQUENCY COMBINED WITH MRD IS AN IMPORTANT BIOMARKER TO PREDICT RELAPSE IN ACUTE MYELOID LEUKEMIA. RESULTS FROM A PROSPECTIVE H102 STUDY
EHA Learning Center, W Zeijlemaker, 181400
INTEGRATIVE ANALYSIS OF THE GENOME, EPIGENOME, TRANSCRIPTOME AND THREE-DIMENSIONAL CHROMATIN STRUCTURE IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Renee Beekman, 181404
IDENTIFICATION OF ABERRANTLY SPLICED GENES AND DEREGULATED PATHWAYS/GENE ONTOLOGY THEMES IN MYELODYSPLASTIC SYNDROME PATIENTS WITH SPLICING FACTOR GENE MUTATIONS
EHA Learning Center, Andrea Pellagatti, 181409
ALPHA-KETOGLUTURATE EXPOSES METABOLIC VULNERABILITIES IN B-CELL LYMPHOMAS
EHA Learning Center, Ricardo Aguiar, 181413
LONG-TERM HEALTH STATUS AFTER HSC TRANSPLANTATION FOR THALASSEMIA: THE FRENCH EXPERIENCE
EHA Learning Center, Isabelle THURET, 181418
INHIBITION OF THE MYELOID MASTER REGULATOR PU.1 AS A THERAPEUTIC STRATEGY IN ACUTE MYELOID LEUKEMIA
EHA Learning Center, Ileana Antony-Debre, 181422
SHORT-TERM FEEDING OF A HIGH-FAT DIET DISTURBS LIPID RAFT/TGF-ΒETA SIGNALING-MEDIATED QUIESCENCE OF HEMATOPOIETIC STEM CELLS IN C57BL/6J MOUSE BONE MARROW
EHA Learning Center, François Hermetet, 181426
FIRST EVIDENCE DEMONSTRATING ENGRAFTMENT AND REPOPULATION ADVANTAGE OF GENE-CORRECTED HEMATOPOIETIC REPOPULATING CELLS IN NON-CONDITIONED FANCONI ANEMIA PATIENTS
EHA Learning Center, Julian Sevilla, 181431
MINIMAL RESIDUAL DISEASE (MRD) BY MULTIPARAMETER FLOW CYTOMETRY (MFC) IN TRANSPLANT ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM): RESULTS FROM THE EMN02/HO95 PHASE 3 TRIAL
EHA Learning Center, Stefania Oliva, 181389
RITUXIMAB SC AND IV PLUS CHOP SHOW SIMILAR EFFICACY AND SAFETY IN THE RANDOMIZED MABEASE STUDY IN FIRST-LINE DLBCL
EHA Learning Center, Elly Lugtenburg, 181394
GRAFT VERSUS LEUKEMIA EFFECT OF ALLOGENEIC STEM CELL TRANSPLANTATION AND MINIMAL RESIDUAL DISEASE IN PATIENTS WITH AML IN FIRST COMPLETE REMISSION.
EHA Learning Center, Jurjen Versluis, 181399
THE VALUE OF NGS PANEL SEQUENCING TO MOLECULARLY DEFINE MYELOID MALIGNANCIES AND CLARIFY BORDERLINE CASES: A STUDY ON 39 GENES IN 1143 PATIENTS
EHA Learning Center, Constance Baer, 181408
DENOSUMAB INCREASES BONE MINERAL DENSITY IN PATIENTS WITH THALASSEMIA MAJOR AND OSTEOPOROSIS: RESULTS OF A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE BLIND, PHASE 2B CLINICAL TRIAL
EHA Learning Center, Ersi Voskaridou, 181417
BASELINE AND EARLY POST-TREATMENT CLINICAL AND LABORATORY FACTORS ASSOCIATED WITH SEVERE NEUROTOXICITY FOLLOWING 19-28Z CAR T CELLS IN ADULT PATIENTS WITH RELAPSED B-ALL
EHA Learning Center, Eric Smith, 181430
NEXT GENERATION SEQUENCING (NGS) METHODOLOGY FOR DETERMINING CYTOGENETIC RISK STATUS IN THE DARATUMUMAB PHASE 3 CASTOR AND POLLUX STUDIES IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)
EHA Learning Center, Christopher Chiu, 181387
EFFICACY BY CYTOGENETIC RISK STATUS FOR DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE OR BORTEZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
EHA Learning Center, Jesus San-Miguel, 181388
Car-T cells in AML
EHA Learning Center, A. Bondanza, 192911
RITUXIMAB MAINTENANCE AFTER AUTOLOGOUS TEM CELL TRANSPLANTATION PROLONGS SURVIVAL IN YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: FINAL RESULTS OF THE LYMA TRIAL OF THE LYSA/GOELAMS GROUP
EHA Learning Center, Steven LE GOUILL, 181392
POLA-R-CHP: POLATUZUMAB VEDOTIN COMBINED WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, PREDNISONE FOR PATIENTS WITH PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA
EHA Learning Center, Hervé Tilly, 181393
DEEP MOLECULAR RESPONSE TO GILTERITINIB IMPROVES SURVIVAL IN FLT3 MUTATION-POSITIVE RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
EHA Learning Center, Altman Jessica, 181397
RISK-ADAPTED, MRD-DIRECTED THERAPY FOR YOUNG ADULTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA: RESULTS OF THE AML1310 TRIAL OF THE GIMEMA GROUP
EHA Learning Center, A Venditti, 181398
CLINICAL IMPACT OF THE SUBCLONAL ARCHITECTURE AND MUTATIONAL COMPLEXITY IN CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Learning Center, Ferran Nadeu, 181402
FBXW7 MUTATIONS LEAD TO ACCUMULATION OF NOTCH1, HIF1-ΑLPHA AND C-MYC IN CLL CELLS
EHA Learning Center, Viola Meyer-Pannwitt, 181403
Updates in the frontline setting and relapse MM from IMW 2017: An expert roundtable discussion
EHA Learning Center, Delivered by Janssen, 183453
LOW MYBL2 EXPRESSION OBSERVED IN MYELODYSPLASTIC SYNDROME PATIENTS WITH WORSE PROGNOSIS IS ASSOCIATED WITH ALTERED DNA REPAIR MECHANISMS IN HAEMATOPOETIC STEM CELLS
EHA Learning Center, Paloma García, 181406
A NOVEL GENETIC AND MORPHOLOGIC PHENOTYPE OF ARID2-MEDIATED MYELODYSPLASTIC SYNDROMES.
EHA Learning Center, Hideki Makishima, 181407
GENETIC ALTERATIONS INVOLVING PROGRAMMED DEATH LIGANDS IN EPSTEIN-BARR VIRUS-ASSOCIATED LYMPHOMAS
EHA Learning Center, Keisuke Kataoka, 181411
FOXO1 CONTROL CD20 EXPRESSION AND INFLUENCE B-CELL LYMPHOMA RESPONSE TO RITUXIMAB-BASED IMMUNOTHERAPY
EHA Learning Center, Michal Dwojak, 181412
GENE THERAPY FOR BETA THALASSEMIA: INITIAL RESULTS FROM THE PHASE I/II TIGET-BTHAL TRIAL OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS GENETICALLY MODIFIED WITH GLOBE LENTIVIRAL VECTOR
EHA Learning Center, Sarah Marktel, 181415
LUSPATERCEPT INCREASES HEMOGLOBIN AND DECREASES TRANSFUSION BURDEN IN ADULTS WITH Β-THALASSEMIA
EHA Learning Center, Antonio Piga, 181416
FUNCTIONAL PROTEOMICS IDENTIFIES SETD2 AS A CRITICAL EFFECTOR OF MLL FUSION PROTEINS TO SAFEGUARD GENOMIC INTEGRITY.
EHA Learning Center, Anna Skucha, 181420
CEBPA-MUTANT ACUTE MYELOID LEUKEMIA IS SENSITIVE TO SMALL-MOLECULE-MEDIATED INHIBITION OF THE MENIN-MLL INTERACTION
EHA Learning Center, Luisa Schmidt, 181421
STEP-WISE REPROGRAMMING OF ENDOTHELIAL CELLS INTO IMMUNE-COMPETENT HEMATOPOIETIC STEM CELLS
EHA Learning Center, Jose Gabriel Barcia Duran, 181424
MARROW MESENCHYMAL STEM CELLS RESCUE BONE MARROW ENDOTHELIAL CELLS SUFFERING CHEMOTHERAPY STRESS BY TRANSFERRING MITOCHONDRIA THROUGH NANOTUBES
EHA Learning Center, Yonghuai Feng, 181425
WILMS' TUMOR 1 (WT1) RNA-ELECTROPORATED DENDRITIC CELL VACCINATION AS POST-REMISSION TREATMENT TO PREVENT OR DELAY RELAPSE IN ACUTE MYELOID LEUKEMIA: FINAL RESULTS OF A PHASE II STUDY IN 30 PATIENTS
EHA Learning Center, Zwi Berneman, 181428
FIRST-IN-HUMAN MULTICENTER STUDY OF BB2121 ANTI-BCMA CAR T CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED RESULTS
EHA Learning Center, Yi Lin, 181429
All children with sickle cell anemia and an HLA identical sibling should be offered hematopoietic stem cell transplantation
EHA Learning Center, Mariane de Montalembert, 192914
Is transplantation still needed in the era of immunotherapy?
EHA Learning Center, Anna Sureda, 184415
Clonal Evolution in AML
EHA Learning Center, KH Metzeler, 192901
Harnessing T-cell mediated anti-leukemic effect: From unmanipulated donor T-cells to tumor-specific and  genetically modified T-cells
EHA Learning Center, Hans-Jochem Kolb, 184419
Immunosenescence: When And How To Vaccinate Older Patients With Malignant Hemopathies?
EHA Learning Center, Raphael Solana, 184422
RBC hydration defects
EHA Learning Center, Carlo Brugnara, 184429
Immune checkpoint inhibitors
EHA Learning Center, Anas Younes, 184414
Engineering NK cells for the treatment of hematologic malignancies
EHA Learning Center, Katy Rezvani, 184425
The long journey of donor search: From sibling to MUD to cord and haplo transplantation
EHA Learning Center, Eliane Gluckman, 184418
Immunosenescence Or Why Are Older Patients More Sensitive To Malignancies?
EHA Learning Center, Tamas Fulop, 184421
Stomatocytosis and allied disorders
EHA Learning Center, Immacolata Andolfo, 184428
Novel aspects of diagnosis of VT
EHA Learning Center, Menno Huisman, 192909
Microenvironment in lymphoma
EHA Learning Center, Georg Lenz, 184413
From dogs to humans... The 60 year long road of allogeneic stem cell transplantation
EHA Learning Center, Rainer Storb, 184417
Elderly task force in hematology: Chair
EHA Learning Center, Dominique Bron, 184420
Functional diversification of human NK cells
EHA Learning Center, Kalle Malmberg, 184424
RBC membrane transport in health and disease
EHA Learning Center, Giel Bosman, 184427
PEG Filgrastim in SCN
EHA Learning Center, Francesca Fioredda, 184410
Treatment of extranodal marginal zone B-cell lymphomas
EHA Learning Center, Markus Raderer, 184394
Emerging treatments for classical myeloproliferative neoplasms
EHA Learning Center, Claire Harrison, 184398
Although ALL is highly curable with conventional chemotherapy, novel therapeutic approaches are still needed to improve outcomes for high-risk or relapsed ALL, especially in adults.Immunotherapeutic approaches have significantly improved the outcome of R
EHA Learning Center, Josep-Maria Ribera, 184402
The 100.000 genomes project
EHA Learning Center, Willem Ouwehand, 184406
Treatment and sequence in multiple myeloma
EHA Learning Center, Xavier Leleu, 192931
Treatment should be started in every patient with high risk smoldering multiple myeloma
EHA Learning Center, María-Victoria Mateos, 192932
First-line therapy for CLL in 2017
EHA Learning Center, Alessandra Tedeschi, 192933
Diagnosis and management of Von Willebrand Disease
EHA Learning Center, Giancarlo Castaman, 192934
RBC membrane transport in health and disease
EHA Learning Center, Giel Bosman, 192935
The long journey of donor search: From sibling to MUD to cord and haplo transplantation
EHA Learning Center, Eliane Gluckman, 192936
Should low risk MDS be transplanted?
EHA Learning Center, Nicolaus Kröger, 192937
Stop of TKI in CML
EHA Learning Center, Juan Luis Steegmann, 192938
Highlights in MPN
EHA Learning Center, Claire Harrison, 192939
Highlights in ALL
EHA Learning Center, Ajay Vora, 192940
Neurological complications of sickle cell disease
EHA Learning Center, Fenalla Kirkham, 192941
Diagnosis and management of rare bleeding disorders & gene therapy
EHA Learning Center, Gili Kenet, 192942
PET-CT as biomarker for response in Lymphoma?/ Interim-PET as a valid biomarker for early response in malignant lymphoma; when to perform and how to assess
EHA Learning Center, Josee Zijlstra, 192943
Top 3 AML
EHA Learning Center, Gert Ossenkoppele, 192944
Anticoagulation in the frail patient / Anticoagulation in the elderly/frail patient (25min)
EHA Learning Center, Kamphuisen Pieter, 192945
Neutrophil extra cellular traps (NET)
EHA Learning Center, Jean Donadieu, 184409
Update on follicular lymphoma: Time beyond chemotherapy?
EHA Learning Center, Kai Hübel, 184393
Targeting specific mutations in MPN
EHA Learning Center, Ann Mullally, 184397
Immunotherapy of ALL from biology to the clinic and back
EHA Learning Center, Terry Fry, 184401
Syndromes predisposing to hematological malignancies
EHA Learning Center, Christian Kratz, 184405